Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis

Mohr, David C.; Goodkin, Donald E.; Likosky, William; Gatto, Nicole M.; Baumann, Kristen A.; Rudick, Richard A.

doi:10.1001/archneur.1997.00550170015009

Cited by 290 publications

(184 citation statements)

References 10 publications

Supporting

Mentioning

172

Contrasting

Unclassified

Order By: Relevance

“…6,[10][11][12][13][14] The aim of this study was to determine the proportion of patients discontinuing first-line DMTs and to identify the reasons for nonadherence.…”

Section: Resultsmentioning

confidence: 99%

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Alroughani

Thussu

2012

International Journal of MS Care

View full text Add to dashboard Cite

The aim of this retrospective study was to determine the rate of nonadherence to disease-modifying therapies (DMTs) among multiple sclerosis (MS) patients in Kuwait and to identify reasons for patient discontinuation of long-term therapy. Using a newly established MS registry at our institution, we collected data on MS patients' demographics, clinical characteristics, disability measures, and continuation or discontinuation of first-line DMTs. Reasons for nonadherence were divided into four categories: adverse events, inconvenience, perceived lack of efficacy, and physician-documented disease progression. Of 212 eligible patients, 40.1% were found to be nonadherent to first-line DMTs. In the nonadherent group, the female-to-male ratio was 1.75:1 and the mean age at disease onset was 26.8 years. Of this group, 69.4% of patients had a relapsing-remitting course, 18.8% had a secondary progressive course, and 11.8% had clinically isolated syndrome. Compared with the adherent group, the nonadherent group had a shorter mean disease duration (P = .014) and a greater likelihood of having Expanded Disability Status Scale (EDSS) scores of 3 or lower (67.1% vs. 48.0%; P = .007). Inconvenience was the most common reason for nonadherence (32.9%), followed by perceived lack of efficacy (25.9%), adverse events (23.5%), and physician-documented disease progression (17.7%). In summary, the rate of nonadherence to first-line DMTs in MS patients at our institution is considered high. Most nonadherent patients had a short disease duration and low EDSS scores. Inconvenience and perceived lack of efficacy were the most common reasons for nonadherence. The results demonstrate a need to improve treatment adherence among MS patients in Kuwait through providing better patient education, improving communication between patients and health-care providers, defining therapy expectations, and instituting new therapeutic techniques. Int J MS Care. 2012;14:17-24.

show abstract

“…6,[10][11][12][13][14] The aim of this study was to determine the proportion of patients discontinuing first-line DMTs and to identify the reasons for nonadherence.…”

Section: Resultsmentioning

confidence: 99%

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Alroughani

Thussu

2012

International Journal of MS Care

View full text Add to dashboard Cite

show abstract

“…There is also evidence that depression decreases adherence to treatment regimens for MS, and that adherence improves with treatment of depression. [3] Lastly, a recent meta-analysis demonstrates a consistent association between stressful life events and subsequent MS exacerbation. [16] However, there is no definitive evidence that major depressive disorder or other psychiatric disorders affect the neurobiologic course of MS.…”

Section: Impact Of Psychiatric Disorders On Msmentioning

confidence: 98%

Psychiatric Issues in Multiple Sclerosis

Chwastiak

Ehde

2007

Psychiatric Clinics of North America

133

View full text Add to dashboard Cite

“…Psychiatric comorbidity is also associated with poor adherence to therapy (Mohr et al. 1997). Therefore, a better understanding of risk factors for psychiatric comorbidity in MS is needed.…”

Section: Introductionmentioning

confidence: 99%

Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis

et al. 2016

View full text Add to dashboard Cite

BackgroundRisk factors for psychiatric comorbidity in multiple sclerosis (MS) are poorly understood.ObjectiveWe evaluated the association between physical comorbidity and incident depression, anxiety disorder, and bipolar disorder in a MS population relative to a matched general population cohort.MethodsUsing population‐based administrative data from Alberta, Canada we identified 9624 persons with MS, and 41,194 matches. Using validated case definitions, we estimated the incidence of depression, anxiety disorder, and bipolar disorder, and their association with physical comorbidities using Cox regression, adjusting for age, sex, socioeconomic status, and index year.ResultsIn both populations, men had a lower risk of depression and anxiety disorders than women, as did individuals who were ≥45 years versus <45 years at the index date. The risk of bipolar disorder declined with increasing age. The risks of incident depression (HR 1.92; 1.82–2.04), anxiety disorders (HR 1.52; 1.42–1.63), and bipolar disorder (HR 2.67; 2.29–3.11) were higher in the MS population than the matched population. These associations persisted essentially unchanged after adjustment for covariates including physical comorbidities. Multiple physical comorbidities were associated with psychiatric disorders in both populations.ConclusionPersons with MS are at increased risk of psychiatric comorbidity generally, and some physical comorbidities are associated with additional risk.

show abstract

Treatment of Depression Improves Adherence to Interferon Beta-1b Therapy for Multiple Sclerosis

Abstract: These findings support previous findings that patients report increased depression after initiating therapy with IFN beta-1b. Although the source of this depression is unclear, these findings suggest that treating patient-reported depression increases adherence to treatment.

Cited by 290 publications

References 10 publications

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Adherence to First-Line Disease-Modifying Therapy for Multiple Sclerosis in Kuwait

Psychiatric Issues in Multiple Sclerosis

Physical comorbidities increase the risk of psychiatric comorbidity in multiple sclerosis

Contact Info

Product

Resources

About